https://www.regeneronmedical.com/content/a1bPr000000wzAHIAY/srd-dupilumab-amenorrhea-all-indications2025-06-21T01:00:40.000Zhttps://www.regeneronmedical.com/content/a1bPr000000wzAfIAI/srd-dupilumab-use-in-patients-with-covid19-infection-andor-receiving-covid12026-02-26T02:01:03.000Zhttps://www.regeneronmedical.com/content/a1bPr000000wzB0IAI/srd-dupilumab-facial-adverse-events-ad-ped-ad2026-02-26T02:01:04.000Zhttps://www.regeneronmedical.com/content/a1bPr000000wzBHIAY/srd-dupilumab-general-safety-ped-ad2025-05-23T01:00:43.000Zhttps://www.regeneronmedical.com/content/a1bPr000000wzBMIAY/srd-dupilumab-herpes-infections-ad-ped-ad2026-02-26T02:01:04.000Zhttps://www.regeneronmedical.com/content/a1bPr000000wzBNIAY/srd-dupilumab-herpes-infections-eoe-ped-eoe2026-02-26T02:01:04.000Zhttps://www.regeneronmedical.com/content/a1bPr000000wzBRIAY/srd-dupilumab-hypersensitivity-testing-ad-ped-ad2025-05-23T01:00:43.000Zhttps://www.regeneronmedical.com/content/a1bPr000000wzBSIAY/srd-dupilumab-immunogenicity-ad-ped-ad2026-02-26T02:01:03.000Zhttps://www.regeneronmedical.com/content/a1bPr000000wzBmIAI/srd-dupilumab-paresthesia-and-hypoesthesia-ad-ped-ad2026-02-26T02:01:03.000Zhttps://www.regeneronmedical.com/content/a1bPr000000wzBvIAI/srd-dupilumab-presurgical-dosing2026-02-25T15:09:47.000Zhttps://www.regeneronmedical.com/content/a1bPr000000wzBxIAI/srd-dupilumab-psoriasis-and-psoriasiform-dermatitis-all-indications2026-02-25T15:09:48.000Zhttps://www.regeneronmedical.com/content/a1bPr000000wzC5IAI/srd-dupilumab-serum-sickness-all-indications2026-02-25T15:09:48.000Zhttps://www.regeneronmedical.com/content/a1bPr000000wzCLIAY/srd-dupilumab-use-in-immunocompromised-patients2026-02-25T15:09:49.000Zhttps://www.regeneronmedical.com/content/a1bPr000000wzCOIAY/srd-dupilumab-use-in-patients-with-alopecia-areata2025-05-23T01:00:43.000Zhttps://www.regeneronmedical.com/content/a1bPr000000wzCQIAY/srd-dupilumab-use-in-patients-with-hepatic-impairment2026-02-25T15:09:49.000Zhttps://www.regeneronmedical.com/content/a1bPr000000wzCXIAY/srd-dupilumab-concomitant-use-with-other-biologics2026-03-05T02:00:29.000Zhttps://www.regeneronmedical.com/content/a1bPr000002P5L9IAK/a1bpr000002p5l92025-08-26T15:44:44.000Zhttps://www.regeneronmedical.com/content/a1bPr000002hIILIA2/srd-dupilumab-laboratory-monitoring2026-02-26T02:01:02.000Zhttps://www.regeneronmedical.com/content/a1bPr000002hIINIA2/srd-dupilumab-nausea-vomiting-and-diarrhea-all-indications2026-02-25T15:09:45.000Zhttps://www.regeneronmedical.com/content/a1bPr000002hIIPIA2/srd-dupilumab-type-2-inflammation2026-02-25T15:09:45.000Zhttps://www.regeneronmedical.com/content/a1bPr000002hIISIA2/srd-dupilumab-eosinophilia-ad-ped-ad-pn-csu-bp2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000002hIIXIA2/srd-dupilumab-hypersensitivity-ast-ped-ast-np-copd-afrs2026-02-25T15:09:52.000Zhttps://www.regeneronmedical.com/content/a1bPr000002hIIbIAM/srd-dupilumab-use-with-and-transitioning-tofrom-janus-kinase-jak-inhibitors2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tJKEIA2/srd-dupilumab-arthralgia-and-psoriatic-arthritis-all-indications2026-02-25T15:09:51.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tL2fIAE/srd-dupilumab-switching-to-or-from-dupilumab2026-02-25T15:09:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tL2hIAE/srd-dupilumab-immunogenicity-csu2025-10-06T20:20:50.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tL2jIAE/srd-dupilumab-pharmacokinetics-and-pharmacodynamics-csu2025-10-06T20:20:50.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tL2kIAE/srd-dupilumab-use-of-rescue-therapy-or-procedure-csu2025-10-06T20:20:50.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tL2lIAE/srd-dupilumab-general-efficacy-csu2025-10-06T20:20:51.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tL2nIAE/srd-dupilumab-general-infections-csu2025-10-06T20:20:51.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tL2oIAE/srd-dupilumab-conjunctivitis-csu2025-10-06T20:20:51.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tL2pIAE/srd-dupilumab-hypersensitivity-csu2025-10-06T20:20:40.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tL2qIAE/srd-dupilumab-dosing-and-administration2026-03-05T02:00:29.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tL2rIAE/srd-dupilumab-reinitiation-after-hold-all-indications2026-02-25T15:09:48.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tL2sIAE/srd-dupilumab-use-in-other-skin-conditions2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tL2tIAE/srd-dupilumab-use-in-patients-with-malignancy2026-02-25T15:09:49.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tL2uIAE/srd-dupilumab-use-with-vaccines2026-02-25T15:09:50.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tL2vIAE/srd-dupilumab-helminth-infections-all-indications2026-02-25T15:09:50.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tL2wIAE/srd-dupilumab-use-in-pregnancy-and-lactation2026-02-25T15:09:51.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tL2xIAE/srd-dupilumab-use-in-csu-2-years-to-12-years-of-age2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tL2yIAE/srd-dupilumab-missed-dose-all-indications2026-02-25T15:09:52.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOiEIAU/a1bpr000002toie2025-04-21T10:52:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOiFIAU/a1bpr000002toif2025-04-21T10:52:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOiGIAU/a1bpr000002toig2025-05-12T09:04:20.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOiHIAU/a1bpr000002toih2025-04-21T10:52:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOiIIAU/a1bpr000002toii2025-05-12T09:04:20.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOiJIAU/a1bpr000002toij2025-05-12T09:04:20.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOiKIAU/a1bpr000002toik2025-04-21T10:52:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOiLIAU/a1bpr000002toil2025-05-12T09:04:20.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOiMIAU/a1bpr000002toim2025-04-21T10:52:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOiNIAU/a1bpr000002toin2025-04-21T10:52:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOiOIAU/a1bpr000002toio2025-10-17T14:14:48.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOiPIAU/a1bpr000002toip2025-10-17T14:18:55.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOiRIAU/a1bpr000002toir2025-05-12T09:04:20.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOiSIAU/a1bpr000002tois2025-05-12T09:04:20.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOiTIAU/a1bpr000002toit2025-05-12T09:04:20.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOiUIAU/a1bpr000002toiu2025-04-21T10:52:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOiVIAU/a1bpr000002toiv2025-05-12T09:04:20.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOiWIAU/a1bpr000002toiw2025-05-12T09:04:20.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOiXIAU/a1bpr000002toix2025-05-12T09:04:20.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOiYIAU/a1bpr000002toiy2025-04-21T10:52:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOiZIAU/a1bpr000002toiz2025-04-21T10:52:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOiaIAE/a1bpr000002toia2025-05-12T09:04:20.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOibIAE/a1bpr000002toib2025-04-21T10:52:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tOicIAE/a1bpr000002toic2025-05-12T09:04:20.000Zhttps://www.regeneronmedical.com/content/a1bPr000002tP7tIAE/a1bpr000002tp7t2026-04-17T11:18:43.000Zhttps://www.regeneronmedical.com/content/a1bPr000002uFXtIAM/srd-dupilumab-general-safety-csu2025-10-06T20:20:51.000Zhttps://www.regeneronmedical.com/content/a1bPr0000031ElZIAU/a1bpr0000031elz2025-05-12T07:59:55.000Zhttps://www.regeneronmedical.com/content/a1bPr0000031ElaIAE/a1bpr0000031ela2025-05-12T07:59:55.000Zhttps://www.regeneronmedical.com/content/a1bPr0000034HDRIA2/reacemiplimabcervical-disease-state-modulemay2025-glb2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr0000036hmvIAA/hofhspecialist-teddistorysoft-20242026-03-31T10:27:27.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037DlBIAU/frreacemiplimabcervical-disease-state-modulemay20252025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037DlCIAU/dereacemiplimabcervical-disease-state-modulemay20252025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037DlDIAU/frreacemiplimabcervical-disease-state-modulemay20252025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037DlEIAU/dereacemiplimabcervical-disease-state-modulemay20252025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037DlFIAU/melanoma-disease-state-education-slide-deck-ma-portal2025-10-06T20:21:00.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037gFJIAY/srd-dupilumab-use-in-patients-with-renal-impairment2026-02-26T02:01:02.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037xRRIAY/a1bpr0000037xrr2026-03-31T10:02:46.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037xuTIAQ/a1bpr0000037xut2026-03-31T10:02:46.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037xuUIAQ/a1bpr0000037xuu2025-06-16T15:16:00.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037xuVIAQ/a1bpr0000037xuv2025-06-20T10:58:06.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037xuWIAQ/a1bpr0000037xuw2025-06-20T10:58:06.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037xuXIAQ/a1bpr0000037xux2025-06-20T10:58:06.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037xuYIAQ/a1bpr0000037xuy2025-11-20T19:54:58.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037xuZIAQ/a1bpr0000037xuz2025-06-20T10:58:06.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037xuaIAA/a1bpr0000037xua2025-06-20T10:58:06.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037xubIAA/a1bpr0000037xub2025-06-20T10:58:06.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037xucIAA/a1bpr0000037xuc2025-06-20T10:58:06.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037xudIAA/a1bpr0000037xud2025-06-20T10:58:06.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037xueIAA/a1bpr0000037xue2025-06-20T10:58:06.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037xufIAA/a1bpr0000037xuf2025-06-20T10:58:06.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037xugIAA/a1bpr0000037xug2025-06-20T10:58:06.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037xuhIAA/a1bpr0000037xuh2025-11-20T19:55:49.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037xuiIAA/a1bpr0000037xui2025-05-30T18:45:34.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037xujIAA/a1bpr0000037xuj2025-05-30T18:45:34.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037xukIAA/a1bpr0000037xuk2025-05-30T18:45:34.000Zhttps://www.regeneronmedical.com/content/a1bPr0000037yybIAA/a1bpr0000037yyb2026-02-27T17:20:24.000Zhttps://www.regeneronmedical.com/content/a1bPr0000038cO9IAI/atreacemiplimabcervical-disease-state-modulemay20252025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr00000398xVIAQ/solid-tumor-modular-content-bcc-infographic-epidemiology2025-12-12T15:31:14.000Zhttps://www.regeneronmedical.com/content/a1bPr000003BFreIAG/cscc-disease-state-education-slide-deckma-portal2026-03-16T15:58:00.000Zhttps://www.regeneronmedical.com/content/a1bPr000003BmxFIAS/solid-tumor-modular-content-nsclc-infographic-pathophysiology2025-12-12T15:48:37.000Zhttps://www.regeneronmedical.com/content/a1bPr000003BmxGIAS/solid-tumor-modular-content-nsclc-infographic-epidemiology2025-12-12T15:47:55.000Zhttps://www.regeneronmedical.com/content/a1bPr000003CGgnIAG/atreacemiplimabcervical-disease-state-modulemay20252025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003CGgoIAG/solid-tumor-modular-content-bcc-infographic-pathophysiology2025-12-12T15:32:15.000Zhttps://www.regeneronmedical.com/content/a1bPr000003ECHJIA4/srd-cemiplimab-restarting-treatment-after-discontinuation2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003F3a9IAC/solid-tumor-modular-content-cscc-infographic-epidemiology2025-12-12T15:32:50.000Zhttps://www.regeneronmedical.com/content/a1bPr000003F7yjIAC/a1bpr000003f7yj2025-06-20T10:59:04.000Zhttps://www.regeneronmedical.com/content/a1bPr000003F7ykIAC/a1bpr000003f7yk2025-06-20T10:59:04.000Zhttps://www.regeneronmedical.com/content/a1bPr000003F85BIAS/a1bpr000003f85b2025-06-20T11:02:49.000Zhttps://www.regeneronmedical.com/content/a1bPr000003F85CIAS/a1bpr000003f85c2025-06-20T11:02:49.000Zhttps://www.regeneronmedical.com/content/a1bPr000003F85DIAS/a1bpr000003f85d2025-06-20T11:02:49.000Zhttps://www.regeneronmedical.com/content/a1bPr000003F85EIAS/a1bpr000003f85e2025-06-20T11:02:49.000Zhttps://www.regeneronmedical.com/content/a1bPr000003F85FIAS/a1bpr000003f85f2025-06-20T11:02:49.000Zhttps://www.regeneronmedical.com/content/a1bPr000003F85GIAS/a1bpr000003f85g2025-06-20T11:02:49.000Zhttps://www.regeneronmedical.com/content/a1bPr000003F85HIAS/a1bpr000003f85h2025-06-20T11:02:49.000Zhttps://www.regeneronmedical.com/content/a1bPr000003F85IIAS/a1bpr000003f85i2025-06-20T11:02:49.000Zhttps://www.regeneronmedical.com/content/a1bPr000003F85JIAS/a1bpr000003f85j2025-06-20T11:02:49.000Zhttps://www.regeneronmedical.com/content/a1bPr000003F85KIAS/a1bpr000003f85k2025-06-20T11:02:49.000Zhttps://www.regeneronmedical.com/content/a1bPr000003F85LIAS/a1bpr000003f85l2025-08-25T23:36:50.000Zhttps://www.regeneronmedical.com/content/a1bPr000003F85MIAS/a1bpr000003f85m2025-08-25T23:36:50.000Zhttps://www.regeneronmedical.com/content/a1bPr000003F85NIAS/a1bpr000003f85n2025-08-25T23:36:50.000Zhttps://www.regeneronmedical.com/content/a1bPr000003F85OIAS/a1bpr000003f85o2025-06-20T11:02:49.000Zhttps://www.regeneronmedical.com/content/a1bPr000003F85PIAS/a1bpr000003f85p2025-08-25T23:36:50.000Zhttps://www.regeneronmedical.com/content/a1bPr000003F85QIAS/a1bpr000003f85q2025-08-25T23:36:50.000Zhttps://www.regeneronmedical.com/content/a1bPr000003F85RIAS/a1bpr000003f85r2025-08-25T23:36:50.000Zhttps://www.regeneronmedical.com/content/a1bPr000003F8DFIA0/a1bpr000003f8df2026-04-06T21:29:16.000Zhttps://www.regeneronmedical.com/content/a1bPr000003FQlFIAW/srd-dupilumab-pharmacokinetics-and-pharmacodynamics-bp2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003FQlGIAW/srd-dupilumab-immunogenicity-bp2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003FQlHIAW/srd-dupilumab-conjunctivitis-bp2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003FQlIIAW/srd-dupilumab-hypersensitivity-bp2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003FQlJIAW/srd-dupilumab-general-infections-bp2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003FQlKIAW/srd-dupilumab-general-efficacy-bp2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003FQlLIAW/srd-dupilumab-general-safety-bp2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003FzpWIAS/nsclc-disease-state-education-slide-deckma-portal2025-10-06T20:21:00.000Zhttps://www.regeneronmedical.com/content/a1bPr000003GZOHIA4/nhl-modular-content-fl-unmet-needs-disease-state-education-infographic2025-11-20T19:48:53.000Zhttps://www.regeneronmedical.com/content/a1bPr000003HevNIAS/srd-dupilumab-asthma-open-label-extension-studies2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003I4Y5IAK/ussrd-cemiplimab-cpost-study2025-10-10T01:00:31.000Zhttps://www.regeneronmedical.com/content/a1bPr000003JBqrIAG/ussrd-cemiplimab-latex2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003JBqtIAG/ussrd-cemiplimab-extravasation2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003JBquIAG/ussrd-cemiplimab-pseudoprogression2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003JBqvIAG/ussrd-cemiplimab-storage-and-stability-for-unopened-vials2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003JBqwIAG/ussrd-cemiplimab-mechanism-of-action2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003JBqxIAG/ussrd-cemiplimab-description-of-the-molecule-and-drug-product2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003JBqzIAG/ussrd-cemiplimab-use-as-neoadjuvant-therapy-in-advanced-solid-tumors2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003JjcXIAS/ussrd-linvoseltamab-phase-3-study-design-in-rrmm-linkermm32026-04-03T01:00:40.000Zhttps://www.regeneronmedical.com/content/a1bPr000003JjcZIAS/ussrd-linvoseltamab-mechanism-of-action2026-01-22T02:00:41.000Zhttps://www.regeneronmedical.com/content/a1bPr000003KBC5IAO/ussrd-linvoseltamab-drug-interactions2026-01-22T02:00:39.000Zhttps://www.regeneronmedical.com/content/a1bPr000003KBC7IAO/ussrd-linvoseltamab-hepatic-function2026-01-22T02:00:40.000Zhttps://www.regeneronmedical.com/content/a1bPr000003KBC8IAO/ussrd-linvoseltamab-storage-and-stability2026-01-22T02:00:40.000Zhttps://www.regeneronmedical.com/content/a1bPr000003KBCEIA4/ussrd-linvoseltamab-renal-function2026-01-22T02:00:40.000Zhttps://www.regeneronmedical.com/content/a1bPr000003LeQXIA0/srd-dupilumab-use-in-pediatric-patients-crswnp2025-10-06T20:20:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003LeQYIA0/srd-dupilumab-hypersensitivity-eoe-ped-eoe2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003LeQZIA0/srd-dupilumab-hypersensitivity-pn2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003LeQaIAK/srd-dupilumab-doses-studied-ast2026-02-26T02:01:03.000Zhttps://www.regeneronmedical.com/content/a1bPr000003LeQbIAK/srd-dupilumab-use-of-rescue-therapy-eoe2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003LeQdIAK/srd-dupilumab-effect-on-need-for-surgery-np2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003LeQeIAK/srd-dupilumab-efficacy-by-baseline-biomarkers-ast-ped-ast2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003LeQgIAK/srd-dupilumab-general-efficacy-ast2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003LeQhIAK/srd-dupilumab-general-efficacy-eoe2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003LeQiIAK/srd-dupilumab-general-efficacy-infant-ad2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003LeQjIAK/srd-dupilumab-general-efficacy-ped-ad2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003LeQlIAK/srd-dupilumab-general-safety-ast2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003LeQmIAK/srd-dupilumab-relapse-after-treatment-discontinuation-ad2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003LeQnIAK/srd-dupilumab-travel-guidelines-and-storage2026-02-26T02:01:04.000Zhttps://www.regeneronmedical.com/content/a1bPr000003LeQoIAK/srd-dupilumab-drug-interactions-with-immunosuppressants-ad2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003LeQqIAK/srd-dupilumab-general-infections-np2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003LeQrIAK/srd-dupilumab-use-in-aerdnsaiderd-np2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003LeQsIAK/srd-dupilumab-product-viability-after-temperature-excursion-patients-and-cons2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003LeQtIAK/srd-dupilumab-product-viability-after-temperature-excursion-hcps-distributor2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003LeQuIAK/srd-dupilumab-drugdrug-interactions2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003MEiXIAW/solid-tumor-modular-content-cscc-infographic-pathophysiology2025-12-12T15:33:14.000Zhttps://www.regeneronmedical.com/content/a1bPr000003OUUfIAO/ovarian-cancer-disease-state-education-slide-deck-ma-portal2025-10-06T20:21:01.000Zhttps://www.regeneronmedical.com/content/a1bPr000003PptdIAC/a1bpr000003pptd2025-09-17T04:41:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003PpteIAC/a1bpr000003ppte2025-07-18T09:56:19.000Zhttps://www.regeneronmedical.com/content/a1bPr000003PpwrIAC/a1bpr000003ppwr2025-07-18T10:01:52.000Zhttps://www.regeneronmedical.com/content/a1bPr000003PpwsIAC/a1bpr000003ppws2026-03-31T10:02:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003SwQjIAK/srd-dupilumab-efficacy-by-baseline-eosinophils-copd2025-09-29T15:27:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003THzqIAG/basal-cell-carcinoma-bcc-disease-state-education-slide-deckma-portal2025-10-06T20:20:59.000Zhttps://www.regeneronmedical.com/content/a1bPr000003TyjpIAC/nhl-modular-content-fl-mini-slide-deck2025-11-20T19:52:50.000Zhttps://www.regeneronmedical.com/content/a1bPr000003U1crIAC/a1bpr000003u1cr2025-08-05T11:59:15.000Zhttps://www.regeneronmedical.com/content/a1bPr000003U1jJIAS/a1bpr000003u1jj2025-08-05T12:05:07.000Zhttps://www.regeneronmedical.com/content/a1bPr000003U1jKIAS/a1bpr000003u1jk2025-08-05T12:05:07.000Zhttps://www.regeneronmedical.com/content/a1bPr000003U1jLIAS/a1bpr000003u1jl2025-08-05T12:05:07.000Zhttps://www.regeneronmedical.com/content/a1bPr000003U1jMIAS/a1bpr000003u1jm2025-08-05T12:05:07.000Zhttps://www.regeneronmedical.com/content/a1bPr000003U1jNIAS/a1bpr000003u1jn2025-08-05T12:05:07.000Zhttps://www.regeneronmedical.com/content/a1bPr000003U1jOIAS/a1bpr000003u1jo2025-08-05T12:05:07.000Zhttps://www.regeneronmedical.com/content/a1bPr000003U1jPIAS/a1bpr000003u1jp2025-08-05T12:05:07.000Zhttps://www.regeneronmedical.com/content/a1bPr000003U1jQIAS/a1bpr000003u1jq2025-08-05T12:05:07.000Zhttps://www.regeneronmedical.com/content/a1bPr000003U1jRIAS/a1bpr000003u1jr2025-08-05T12:05:07.000Zhttps://www.regeneronmedical.com/content/a1bPr000003U1jSIAS/a1bpr000003u1js2025-08-05T12:05:07.000Zhttps://www.regeneronmedical.com/content/a1bPr000003U1jTIAS/a1bpr000003u1jt2025-08-05T12:05:07.000Zhttps://www.regeneronmedical.com/content/a1bPr000003U1jUIAS/a1bpr000003u1ju2025-08-05T12:05:07.000Zhttps://www.regeneronmedical.com/content/a1bPr000003U1jVIAS/a1bpr000003u1jv2025-08-05T12:05:07.000Zhttps://www.regeneronmedical.com/content/a1bPr000003U1jWIAS/a1bpr000003u1jw2025-08-05T12:05:07.000Zhttps://www.regeneronmedical.com/content/a1bPr000003U1jXIAS/a1bpr000003u1jx2025-08-05T12:05:07.000Zhttps://www.regeneronmedical.com/content/a1bPr000003U1jYIAS/a1bpr000003u1jy2025-08-05T12:05:07.000Zhttps://www.regeneronmedical.com/content/a1bPr000003U1jZIAS/a1bpr000003u1jz2025-08-05T12:05:07.000Zhttps://www.regeneronmedical.com/content/a1bPr000003ULenIAG/solid-tumor-modular-content-nsclc-infographic-enviromental-and-occupational-r2026-04-07T21:15:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003VpNtIAK/video-overview-of-nsclc-disparities2025-10-28T20:46:26.000Zhttps://www.regeneronmedical.com/content/a1bPr000003XkFFIA0/prostate-cancer-disease-state-education-slide-deck-ma-portal2026-02-03T17:03:09.000Zhttps://www.regeneronmedical.com/content/a1bPr000003b0nJIAQ/solid-tumor-modular-content-ovarian-cancer-infographic-epidemiology2025-12-12T17:05:09.000Zhttps://www.regeneronmedical.com/content/a1bPr000003b0nKIAQ/solid-tumor-modular-content-nsclc-infographic-va2025-12-12T15:49:09.000Zhttps://www.regeneronmedical.com/content/a1bPr000003bRXNIA2/gynecological-cancer-care-in-the-va-infographic2026-04-07T21:17:45.000Zhttps://www.regeneronmedical.com/content/a1bPr000003cH4YIAU/cscc-high-risk-disease-state-education-slide-deck-ma-portal2025-10-16T16:40:29.000Zhttps://www.regeneronmedical.com/content/a1bPr000003d4oPIAQ/a1bpr000003d4op2025-09-08T11:38:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003d4oQIAQ/a1bpr000003d4oq2025-09-08T11:38:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003d4oRIAQ/a1bpr000003d4or2025-09-08T11:38:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003d4oSIAQ/a1bpr000003d4os2025-09-08T11:38:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003d4oTIAQ/a1bpr000003d4ot2025-09-08T11:38:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpNIAU/a1bpr000003erpn2025-09-22T23:19:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpOIAU/a1bpr000003erpo2025-09-22T23:19:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpPIAU/a1bpr000003erpp2025-09-22T23:19:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpQIAU/a1bpr000003erpq2025-09-22T23:19:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpRIAU/a1bpr000003erpr2025-09-22T23:32:10.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpSIAU/a1bpr000003erps2025-09-22T23:19:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpTIAU/a1bpr000003erpt2025-09-22T23:19:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpUIAU/a1bpr000003erpu2025-09-22T23:19:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpVIAU/a1bpr000003erpv2025-09-22T23:19:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpWIAU/a1bpr000003erpw2025-09-22T23:19:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpXIAU/a1bpr000003erpx2025-09-22T23:19:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpYIAU/a1bpr000003erpy2025-09-22T23:19:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpZIAU/a1bpr000003erpz2025-09-22T23:19:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpaIAE/a1bpr000003erpa2025-09-22T23:19:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpbIAE/a1bpr000003erpb2025-09-22T23:19:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpcIAE/a1bpr000003erpc2025-09-22T23:19:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpdIAE/a1bpr000003erpd2025-09-12T09:54:16.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpeIAE/a1bpr000003erpe2025-09-12T09:54:16.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpfIAE/a1bpr000003erpf2025-09-12T09:54:16.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpgIAE/a1bpr000003erpg2025-09-12T09:54:16.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRphIAE/a1bpr000003erph2025-09-12T09:54:16.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpiIAE/a1bpr000003erpi2025-09-12T09:54:16.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpjIAE/a1bpr000003erpj2025-09-12T09:54:16.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRpkIAE/a1bpr000003erpk2025-09-12T09:54:16.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRqzIAE/a1bpr000003erqz2025-09-12T09:56:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eRr0IAE/a1bpr000003err02025-11-20T19:59:24.000Zhttps://www.regeneronmedical.com/content/a1bPr000003eidKIAQ/rvo-infographic-overview-and-epidemiology2026-04-07T21:16:47.000Zhttps://www.regeneronmedical.com/content/a1bPr000003gJanIAE/a1bpr000003gjan2026-03-31T10:02:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003gJaoIAE/a1bpr000003gjao2025-09-19T09:49:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000003gJapIAE/a1bpr000003gjap2025-09-19T09:49:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000003gJaqIAE/a1bpr000003gjaq2025-09-19T09:49:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000003gJarIAE/a1bpr000003gjar2025-10-15T10:34:21.000Zhttps://www.regeneronmedical.com/content/a1bPr000003gJasIAE/a1bpr000003gjas2025-09-19T09:49:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000003gJatIAE/a1bpr000003gjat2025-09-19T09:49:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000003gJauIAE/a1bpr000003gjau2025-09-19T09:49:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000003gJfdIAE/a1bpr000003gjfd2025-09-19T10:05:02.000Zhttps://www.regeneronmedical.com/content/a1bPr000003gJfeIAE/a1bpr000003gjfe2025-09-19T10:05:02.000Zhttps://www.regeneronmedical.com/content/a1bPr000003gJffIAE/a1bpr000003gjff2026-03-31T10:02:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003h5KTIAY/prohofh-mod-animated-interactiveaug20252026-03-31T10:27:45.000Zhttps://www.regeneronmedical.com/content/a1bPr000003h5KUIAY/prohofh-mod-summary-videoaug20252026-03-31T10:28:03.000Zhttps://www.regeneronmedical.com/content/a1bPr000003k7ETIAY/jpsrd-cemiplimab-empowerlung-3-results-in-the-pdl11-population2025-10-02T01:00:23.000Zhttps://www.regeneronmedical.com/content/a1bPr000003l2z7IAA/srd-dupilumab-general-efficacy-pn2025-10-04T01:00:25.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRKpIAM/srdveopozimmunogenicity-and-adas18aug20252025-10-06T20:20:19.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRKtIAM/srdveopozstability-temperature-excursions23jul20252025-10-06T20:20:20.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRKxIAM/srdveopozinvestigatorinitiated-study-program17jul20252025-10-06T20:20:22.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRKyIAM/srdveopozcompassionate-use17jul20252025-10-06T20:20:22.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRKzIAM/srdveopozapproval-status-and-availability17jul20252025-10-06T20:20:22.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRL0IAM/rea-pulsar-96wk-ped-lai-asrs-20252025-10-06T20:20:23.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRL4IAM/srdevkeezause-with-other-biologics2025-10-06T20:20:24.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRL5IAM/srdevkeezamechanism-of-action2025-10-06T20:20:25.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRL7IAM/srdevkeezaonset-of-action2025-10-06T20:20:25.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRL9IAM/srdevkeezaoverdose2025-10-06T20:20:26.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRLAIA2/srdevkeezarefractory-hypercholesterolemia06oct20232025-10-06T20:20:26.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRLBIA2/srdevkeezause-in-pediatrics2025-10-06T20:20:26.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRLDIA2/srdevkeezastorage-and-handling11jan20222025-10-06T20:20:27.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRLEIA2/srdevkeezashelf-life2025-10-06T20:20:28.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRLGIA2/srdevkeezastability-and-temperature-excursions31jan20232025-10-06T20:20:28.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRLHIA2/srdevkeezaapproval-status-and-availability2025-10-06T20:20:28.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRLKIA2/pro-email-template-for-evinacumab-approval-in-pediatric-patients-5-years-old2025-10-06T20:20:30.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRLMIA2/srdevkeezaallergic-reactions2025-10-06T20:20:31.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRLNIA2/srdevkeezaapheresis2025-10-06T20:20:31.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRLOIA2/srdevkeezaclinical-practice-guidelines2025-10-06T20:20:31.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRLQIA2/srdevkeezadosage-and-administration2025-10-06T20:20:32.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRLTIA2/srdevkeezageneral-safety-and-tolerability2025-10-06T20:20:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRLUIA2/srdevkeezagenetics-angptl3-lof2025-10-06T20:20:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRLVIA2/srdevkeezaglucose-metabolism2025-10-06T20:20:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRLWIA2/srdevkeezahepatic-aes2025-10-06T20:20:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRLZIA2/srdpraluentsample-request2025-10-06T20:20:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRLaIAM/srdpraluentswitching-to-or-from-pcsk9-inhibitors2025-10-06T20:20:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRLbIAM/srdpraluentmusculoskeletal-related-events-and-creatine-kinase2025-10-06T20:20:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRLcIAM/srdpraluentmanufacturing-process23sep20252025-10-06T20:20:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRLeIAM/srdpraluentingredients-and-device-information2025-10-06T20:20:36.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lRLmIAM/ussrd-linvoseltamab-phase-2-study-design-and-results-in-highrisk-smm-linker2026-01-22T02:00:39.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lWFdIAM/reausunbaudamplify-sponsored-genetic-testing-program-overviewsep20252025-10-07T01:00:30.000Zhttps://www.regeneronmedical.com/content/a1bPr000003lZv3IAE/a1bpr000003lzv32026-03-16T15:56:50.000Zhttps://www.regeneronmedical.com/content/a1bPr000003ojY5IAI/a1bpr000003ojy52025-10-15T10:28:09.000Zhttps://www.regeneronmedical.com/content/a1bPr000003ojY6IAI/a1bpr000003ojy62025-10-15T10:28:09.000Zhttps://www.regeneronmedical.com/content/a1bPr000003ojY7IAI/a1bpr000003ojy72025-10-15T10:28:09.000Zhttps://www.regeneronmedical.com/content/a1bPr000003ojY8IAI/a1bpr000003ojy82025-10-15T10:28:09.000Zhttps://www.regeneronmedical.com/content/a1bPr000003ojY9IAI/a1bpr000003ojy92025-10-15T10:28:09.000Zhttps://www.regeneronmedical.com/content/a1bPr000003ojYAIAY/a1bpr000003ojya2025-10-24T13:28:26.000Zhttps://www.regeneronmedical.com/content/a1bPr000003ojYBIAY/a1bpr000003ojyb2025-10-24T13:28:26.000Zhttps://www.regeneronmedical.com/content/a1bPr000003ojYCIAY/a1bpr000003ojyc2025-11-20T19:58:41.000Zhttps://www.regeneronmedical.com/content/a1bPr000003ojYDIAY/a1bpr000003ojyd2025-10-24T13:28:26.000Zhttps://www.regeneronmedical.com/content/a1bPr000003ojYEIAY/a1bpr000003ojye2025-10-24T13:28:26.000Zhttps://www.regeneronmedical.com/content/a1bPr000003ojYFIAY/a1bpr000003ojyf2025-11-20T19:58:07.000Zhttps://www.regeneronmedical.com/content/a1bPr000003ojYGIAY/a1bpr000003ojyg2025-10-24T13:28:26.000Zhttps://www.regeneronmedical.com/content/a1bPr000003ojcvIAA/a1bpr000003ojcv2025-10-15T10:36:17.000Zhttps://www.regeneronmedical.com/content/a1bPr000003q16MIAQ/solid-tumor-modular-content-prostate-cancer-infographic-epidemiology2025-10-18T01:00:26.000Zhttps://www.regeneronmedical.com/content/a1bPr000003q16NIAQ/auditory-content-impact-of-hearing-loss2026-03-16T15:55:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000003qWN3IAM/srdevkeezasugar-content2025-10-21T01:00:54.000Zhttps://www.regeneronmedical.com/content/a1bPr000003qWN4IAM/mm-frailty-infographic2026-04-07T21:15:09.000Zhttps://www.regeneronmedical.com/content/a1bPr000003rjbZIAQ/ussrd-cemiplimab-use-in-immunocompromised-immunosuppressed-patients2025-10-23T01:00:47.000Zhttps://www.regeneronmedical.com/content/a1bPr000003rjbaIAA/crs-fact-sheet2026-04-07T21:14:30.000Zhttps://www.regeneronmedical.com/content/a1bPr000003syNFIAY/multiple-myeloma-infographic2025-10-25T01:00:29.000Zhttps://www.regeneronmedical.com/content/a1bPr000003tTkPIAU/ophthalmology-modular-content-namd-dse-mini-slide-deck2025-10-29T01:00:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uVIjIAM/rvo-infographic-brvo-and-crvo2026-04-07T21:16:26.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwCTIAY/srd-dupilumab-overdose2025-10-31T01:00:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwCUIAY/srd-dupilumab-use-in-immune-checkpointrelated-toxicity2026-02-22T02:00:41.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwCVIAY/srd-dupilumab-general-safety-copd2025-10-31T01:00:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwCWIAY/srd-dupilumab-injection-site-reactions2026-02-25T15:09:43.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwCXIAY/srd-dupilumab-hepatic-adverse-events-all-indications2026-02-25T15:09:43.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwCYIAY/srd-dupilumab-immunogenicity-ast-np-eoe-copd-afrs2026-02-25T15:09:45.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwCZIAY/srd-dupilumab-incidence-of-alopecia-ad-ped-ad2025-10-31T01:00:58.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwCaIAI/srd-dupilumab-ingredients-and-formulation2025-10-31T01:00:58.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwCbIAI/srd-dupilumab-cardiovascular-disorders-all-indications2026-02-25T15:09:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwCcIAI/srd-dupilumab-comparative-studies-np2025-10-31T01:00:58.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwCdIAI/srd-dupilumab-conjunctivitis-and-osd-management-in-published-literature2025-10-31T01:00:58.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwCeIAI/srd-dupilumab-effect-on-ige-ad-ped-ad2025-10-31T01:00:58.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwCfIAI/srd-dupilumab-eosinophilia-np-eoe-ped-eoe-afrs2026-02-25T15:09:47.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwCgIAI/srd-dupilumab-general-efficacy-ad2025-10-31T01:00:58.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwChIAI/srd-dupilumab-general-safety-ad2025-10-31T01:00:59.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwCiIAI/srd-dupilumab-general-safety-eoe2025-10-31T01:00:59.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwCjIAI/srd-dupilumab-pharmacokinetics-eoe-ped-eoe2025-10-31T01:00:59.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwCkIAI/srd-dupilumab-use-in-patients-with-food-allergies2025-10-31T01:00:59.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwClIAI/srd-dupilumab-weight-change-all-indications2026-02-25T15:09:50.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwCmIAI/srd-dupilumab-erefs-efficacy-results-eoe-ped-eoe2025-10-31T01:00:59.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwCnIAI/srd-dupilumab-every-4-week-dosing-np2025-10-31T01:00:59.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwCoIAI/srd-dupilumab-herpes-infections-ast-ped-ast-np-copd-afrs2026-02-25T15:09:52.000Zhttps://www.regeneronmedical.com/content/a1bPr000003uwCpIAI/srd-dupilumab-use-in-chronic-rhinosinusitis-without-nasal-polyposis-crssnp2025-10-31T01:01:00.000Zhttps://www.regeneronmedical.com/content/a1bPr000003vP3BIAU/a1bpr000003vp3b2025-11-03T10:44:25.000Zhttps://www.regeneronmedical.com/content/a1bPr000003vP3CIAU/a1bpr000003vp3c2025-11-03T10:44:25.000Zhttps://www.regeneronmedical.com/content/a1bPr000003vujhIAA/ussrd-linvoseltamab-use-of-dexamethasone-20-mg-premedication-and-crs-in-linke2026-01-22T02:00:40.000Zhttps://www.regeneronmedical.com/content/a1bPr000003vujiIAA/ussrd-linvoseltamab-number-of-patients-who-received-igg-supplementation-in-li2026-01-22T02:00:40.000Zhttps://www.regeneronmedical.com/content/a1bPr000003wQEvIAM/ussrd-cemiplimab-phase-2-neoadjuvant-cscc-study-design-and-results-study-1902025-11-05T02:00:31.000Zhttps://www.regeneronmedical.com/content/a1bPr000003wQEwIAM/ussrd-cemiplimab-renal-function2025-11-05T02:00:31.000Zhttps://www.regeneronmedical.com/content/a1bPr000003wQExIAM/crs-disease-state-education-mini-deck2025-11-20T19:44:20.000Zhttps://www.regeneronmedical.com/content/a1bPr000003y053IAA/srdevkeezaeffect-on-hdlc2025-11-08T02:00:32.000Zhttps://www.regeneronmedical.com/content/a1bPr000003y054IAA/ussrd-cemiplimab-prespecified-histology-and-pdl1-subgroup-analysis-study-162025-11-08T02:00:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000003y6qPIAQ/a1bpr000003y6qp2025-11-10T13:51:44.000Zhttps://www.regeneronmedical.com/content/a1bPr000003y6s1IAA/a1bpr000003y6s12025-11-10T10:28:05.000Zhttps://www.regeneronmedical.com/content/a1bPr000003y6s2IAA/a1bpr000003y6s22025-11-10T13:48:30.000Zhttps://www.regeneronmedical.com/content/a1bPr000003y6s3IAA/a1bpr000003y6s32025-11-10T13:54:48.000Zhttps://www.regeneronmedical.com/content/a1bPr000003y6s4IAA/a1bpr000003y6s42025-11-10T13:52:23.000Zhttps://www.regeneronmedical.com/content/a1bPr000003y6s5IAA/a1bpr000003y6s52026-03-31T10:02:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003y6s6IAA/a1bpr000003y6s62026-03-31T10:02:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000003y6s7IAA/a1bpr000003y6s72026-03-31T10:02:46.000Zhttps://www.regeneronmedical.com/content/a1bPr0000040bIDIAY/a1bpr0000040bid2025-11-17T09:43:46.000Zhttps://www.regeneronmedical.com/content/a1bPr0000040bJpIAI/a1bpr0000040bjp2025-12-12T15:53:43.000Zhttps://www.regeneronmedical.com/content/a1bPr0000040bLRIAY/a1bpr0000040blr2026-03-31T10:02:46.000Zhttps://www.regeneronmedical.com/content/a1bPr0000040bLSIAY/a1bpr0000040bls2026-03-31T10:02:46.000Zhttps://www.regeneronmedical.com/content/a1bPr0000041bUfIAI/ophthalmology-modular-content-dme-dse-mini-slide-deck2025-11-19T02:00:45.000Zhttps://www.regeneronmedical.com/content/a1bPr0000042agDIAQ/ussrd-cemiplimab-drug-interactions2025-11-21T02:00:21.000Zhttps://www.regeneronmedical.com/content/a1bPr0000042agEIAQ/ussrd-cemiplimab-brain-metastases-subgroup-analyses-in-empowerlung-1-and-emp2025-11-21T02:00:22.000Zhttps://www.regeneronmedical.com/content/a1bPr0000042agFIAQ/ussrd-cemiplimab-exploratory-analyses-of-ansclc-patients-with-squamous-histol2025-11-21T02:00:22.000Zhttps://www.regeneronmedical.com/content/a1bPr0000042agGIAQ/ussrd-cemiplimab-anogenitalhpv-cscc2025-11-21T02:00:22.000Zhttps://www.regeneronmedical.com/content/a1bPr0000042agHIAQ/video-overview-of-the-multifaceted-impact-of-congenital-hearing-loss2025-11-21T02:00:22.000Zhttps://www.regeneronmedical.com/content/a1bPr00000430XRIAY/srdevkeezalatex-content2025-11-22T02:00:34.000Zhttps://www.regeneronmedical.com/content/a1bPr0000043WSTIA2/a1bpr0000043wst2025-12-05T11:11:44.000Zhttps://www.regeneronmedical.com/content/a1bPr0000043WSUIA2/a1bpr0000043wsu2025-12-05T11:11:44.000Zhttps://www.regeneronmedical.com/content/a1bPr0000043WSVIA2/a1bpr0000043wsv2025-12-05T11:11:44.000Zhttps://www.regeneronmedical.com/content/a1bPr0000043WSWIA2/a1bpr0000043wsw2025-12-05T11:11:44.000Zhttps://www.regeneronmedical.com/content/a1bPr0000043WSXIA2/a1bpr0000043wsx2025-12-22T17:28:36.000Zhttps://www.regeneronmedical.com/content/a1bPr0000043WSYIA2/a1bpr0000043wsy2025-12-18T10:31:17.000Zhttps://www.regeneronmedical.com/content/a1bPr0000043WSZIA2/a1bpr0000043wsz2025-12-05T11:12:45.000Zhttps://www.regeneronmedical.com/content/a1bPr0000043WSaIAM/a1bpr0000043wsa2025-12-05T11:11:44.000Zhttps://www.regeneronmedical.com/content/a1bPr0000043WSbIAM/a1bpr0000043wsb2025-12-05T11:11:44.000Zhttps://www.regeneronmedical.com/content/a1bPr0000043WScIAM/a1bpr0000043wsc2025-12-05T11:11:44.000Zhttps://www.regeneronmedical.com/content/a1bPr0000043WSdIAM/a1bpr0000043wsd2025-12-05T11:11:44.000Zhttps://www.regeneronmedical.com/content/a1bPr0000043WVhIAM/a1bpr0000043wvh2025-12-05T11:11:44.000Zhttps://www.regeneronmedical.com/content/a1bPr0000043sb3IAA/ussrd-linvoseltamab-use-in-postbcma-car-tcell-therapy-patients2026-01-22T02:00:41.000Zhttps://www.regeneronmedical.com/content/a1bPr0000046XdJIAU/ussrd-cemiplimab-infusionrelated-reactions2025-12-05T02:00:41.000Zhttps://www.regeneronmedical.com/content/a1bPr0000046ZIXIA2/a1bpr0000046zix2025-12-18T10:31:17.000Zhttps://www.regeneronmedical.com/content/a1bPr0000046ZIYIA2/a1bpr0000046ziy2025-12-05T11:08:42.000Zhttps://www.regeneronmedical.com/content/a1bPr0000047zqrIAA/srdevkeezause-in-japanese-patients07mar20222025-12-10T02:00:31.000Zhttps://www.regeneronmedical.com/content/a1bPr0000048eArIAI/srdevkeezaingredients2025-12-11T02:00:29.000Zhttps://www.regeneronmedical.com/content/a1bPr0000048eAsIAI/srdpraluentstorage-and-rerefrigeration12nov20242025-12-11T02:00:29.000Zhttps://www.regeneronmedical.com/content/a1bPr0000049gtmIAA/ussrd-cemiplimab-serious-adverse-reactions-in-cemiplimab-clinical-trials2025-12-13T02:00:28.000Zhttps://www.regeneronmedical.com/content/a1bPr000004ABhUIAW/srdeylea-hd-latex-content-vial2025-12-16T02:00:30.000Zhttps://www.regeneronmedical.com/content/a1bPr000004ABhVIAW/srdevkeezamissed-dose2025-12-16T02:00:30.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDE9IAO/a1bpr000004bde92025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEAIA4/a1bpr000004bdea2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEBIA4/a1bpr000004bdeb2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDECIA4/a1bpr000004bdec2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEDIA4/a1bpr000004bded2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEEIA4/a1bpr000004bdee2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEFIA4/a1bpr000004bdef2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEGIA4/a1bpr000004bdeg2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEHIA4/a1bpr000004bdeh2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEIIA4/a1bpr000004bdei2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEJIA4/a1bpr000004bdej2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEKIA4/a1bpr000004bdek2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDELIA4/a1bpr000004bdel2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEMIA4/a1bpr000004bdem2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDENIA4/a1bpr000004bden2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEOIA4/a1bpr000004bdeo2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEPIA4/a1bpr000004bdep2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEQIA4/a1bpr000004bdeq2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDERIA4/a1bpr000004bder2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDESIA4/a1bpr000004bdes2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDETIA4/a1bpr000004bdet2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEUIA4/a1bpr000004bdeu2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEVIA4/a1bpr000004bdev2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEWIA4/a1bpr000004bdew2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEXIA4/a1bpr000004bdex2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEYIA4/a1bpr000004bdey2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEZIA4/a1bpr000004bdez2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEaIAO/a1bpr000004bdea2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEbIAO/a1bpr000004bdeb2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEcIAO/a1bpr000004bdec2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEdIAO/a1bpr000004bded2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEeIAO/a1bpr000004bdee2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEfIAO/a1bpr000004bdef2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEgIAO/a1bpr000004bdeg2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEhIAO/a1bpr000004bdeh2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEiIAO/a1bpr000004bdei2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEjIAO/a1bpr000004bdej2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEkIAO/a1bpr000004bdek2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDElIAO/a1bpr000004bdel2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEmIAO/a1bpr000004bdem2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEnIAO/a1bpr000004bden2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEoIAO/a1bpr000004bdeo2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEpIAO/a1bpr000004bdep2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEqIAO/a1bpr000004bdeq2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDErIAO/a1bpr000004bder2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEsIAO/a1bpr000004bdes2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEtIAO/a1bpr000004bdet2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEuIAO/a1bpr000004bdeu2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEvIAO/a1bpr000004bdev2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004BDEwIAO/a1bpr000004bdew2025-12-18T10:30:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004C4qLIAS/srdevkeezaopenlabel-extension-study30jan20252025-12-20T02:00:42.000Zhttps://www.regeneronmedical.com/content/a1bPr000004CuNVIA0/video-overview-of-multiple-myeloma-frailty2026-01-06T18:03:24.000Zhttps://www.regeneronmedical.com/content/a1bPr000004F81NIAS/nhl-modular-content-dlbcl-mini-slide-deck2026-01-07T02:00:39.000Zhttps://www.regeneronmedical.com/content/a1bPr000004GJfWIAW/ussrd-cemiplimab-cemi-chemotherapy-in-nsclc-patients-who-progressed-on-mono2026-01-08T02:00:32.000Zhttps://www.regeneronmedical.com/content/a1bPr000004HnejIAC/srdevkeezaelipse-hofh-16292026-01-14T02:00:36.000Zhttps://www.regeneronmedical.com/content/a1bPr000004IIx3IAG/pro-specialist-hofh-campaign-cascade-screening-infographic-oct-20242026-03-31T10:28:19.000Zhttps://www.regeneronmedical.com/content/a1bPr000004IlSnIAK/solid-tumor-modular-content-ovarian-cancer-infographic-pathophysiology2026-01-15T02:00:31.000Zhttps://www.regeneronmedical.com/content/a1bPr000004JftBIAS/srdevkeezamanaged-access-programs2026-01-17T02:00:31.000Zhttps://www.regeneronmedical.com/content/a1bPr000004JftCIAS/praluentmeasurement-of-lowdensity-lipoprotein-cholesteroljan20262026-01-17T02:00:31.000Zhttps://www.regeneronmedical.com/content/a1bPr000004JftDIAS/highrisk-multiple-myeloma-slide-deck2026-03-16T15:53:53.000Zhttps://www.regeneronmedical.com/content/a1bPr000004KYEXIA4/reaeylea-photon-96-week-angiogenesis-feb-20242026-01-21T02:00:31.000Zhttps://www.regeneronmedical.com/content/a1bPr000004KYEYIA4/reaeylea-hd-pulsar-96-weeksangiogenesis-20242026-01-21T02:00:31.000Zhttps://www.regeneronmedical.com/content/a1bPr000004KYEZIA4/srdeylea-hd-use-in-patients-with-alpha-gal-allergy2026-04-04T01:00:48.000Zhttps://www.regeneronmedical.com/content/a1bPr000004KYEaIAO/rvo-infographic-vegf-role-in-rvo2026-01-21T02:00:31.000Zhttps://www.regeneronmedical.com/content/a1bPr000004L5onIAC/pro-specialist-hofh-campaign-advanced-management-video-oct-20242026-03-31T10:28:41.000Zhttps://www.regeneronmedical.com/content/a1bPr000004L5ooIAC/srdeylea-pfs-room-temperature-excursion2026-01-22T02:00:39.000Zhttps://www.regeneronmedical.com/content/a1bPr000004L5opIAC/srdeylea-pfs-freezing-temperature-excursion2026-01-22T02:00:39.000Zhttps://www.regeneronmedical.com/content/a1bPr000004LimvIAC/ussrd-cemiplimab-phase-3-advanced-nsclc-study-design-and-results-combo2026-01-23T02:00:43.000Zhttps://www.regeneronmedical.com/content/a1bPr000004LimwIAC/ussrd-linvoseltamab-phase-12-study-design-and-results-in-newly-diagnosed-mm2026-04-03T01:00:40.000Zhttps://www.regeneronmedical.com/content/a1bPr000004LimxIAC/ussrd-linvoseltamab-phase-1b-study-design-and-results-in-rrmm-linkermm22026-04-03T01:00:40.000Zhttps://www.regeneronmedical.com/content/a1bPr000004MAknIAG/icans-disease-state-education-mini-deck2026-01-24T02:00:22.000Zhttps://www.regeneronmedical.com/content/a1bPr000004MAkoIAG/solid-tumor-modular-content-cscc-infographic-nodal-vs-nonnodal2026-01-24T02:00:23.000Zhttps://www.regeneronmedical.com/content/a1bPr000004NlFFIA0/srdeylea-pfs-silicone-oil-content2026-01-29T02:00:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000004PA6jIAG/nhl-modular-content-dlbcl-unmet-needs-disease-state-education-infographic2026-02-04T02:00:40.000Zhttps://www.regeneronmedical.com/content/a1bPr000004QgVxIAK/melanoma-in-veterans-understanding-the-disproportionate-impact2026-02-07T02:00:28.000Zhttps://www.regeneronmedical.com/content/a1bPr000004RFNFIA4/srdevkeezapregnancy-breastfeeding-and-fertility2026-02-07T02:00:28.000Zhttps://www.regeneronmedical.com/content/a1bPr000004Rr61IAC/ussrd-linvoseltamab-serious-adverse-events2026-02-10T02:00:31.000Zhttps://www.regeneronmedical.com/content/a1bPr000004Rr62IAC/ussrd-linvoseltamab-neurotoxicity-icans2026-02-10T02:00:31.000Zhttps://www.regeneronmedical.com/content/a1bPr000004Rr63IAC/ussrd-linvoseltamab-cytokine-release-syndrome2026-02-10T02:00:31.000Zhttps://www.regeneronmedical.com/content/a1bPr000004Rr64IAC/ussrd-linvoseltamab-infusionrelated-reactions2026-02-10T02:00:32.000Zhttps://www.regeneronmedical.com/content/a1bPr000004Rr65IAC/ussrd-linvoseltamab-infections2026-02-10T02:00:32.000Zhttps://www.regeneronmedical.com/content/a1bPr000004SO8LIAW/solid-tumor-modular-content-nsclc-infographic-squamous-vs-nonsquamous2026-02-27T02:00:23.000Zhttps://www.regeneronmedical.com/content/a1bPr000004SQtJIAW/a1bpr000004sqtj2026-02-12T00:15:49.000Zhttps://www.regeneronmedical.com/content/a1bPr000004SQtKIAW/a1bpr000004sqtk2026-02-11T12:02:13.000Zhttps://www.regeneronmedical.com/content/a1bPr000004SQtLIAW/a1bpr000004sqtl2026-02-11T12:02:13.000Zhttps://www.regeneronmedical.com/content/a1bPr000004SQtMIAW/a1bpr000004sqtm2026-02-11T12:02:13.000Zhttps://www.regeneronmedical.com/content/a1bPr000004SQtNIAW/a1bpr000004sqtn2026-02-11T12:02:13.000Zhttps://www.regeneronmedical.com/content/a1bPr000004TN29IAG/auditory-content-otoferlinrelated-hearing-loss-mini-deck2026-04-17T15:51:22.000Zhttps://www.regeneronmedical.com/content/a1bPr000004TN2AIAW/video-overview-of-gynecological-cancers-in-us-veterans2026-02-13T02:00:43.000Zhttps://www.regeneronmedical.com/content/a1bPr000004VTeXIAW/ussrd-linvoseltamab-phase-2-study-design-in-hrmgus-or-nhrsmm-linkermgus12026-02-19T02:00:23.000Zhttps://www.regeneronmedical.com/content/a1bPr000004VTeYIAW/ussrd-linvoseltamab-latex-content2026-02-19T02:00:24.000Zhttps://www.regeneronmedical.com/content/a1bPr000004VxPhIAK/ussrd-cemiplimab-use-as-adjuvant-therapy-in-advanced-solid-tumors2026-02-20T02:00:43.000Zhttps://www.regeneronmedical.com/content/a1bPr000004VxPiIAK/ussrd-linvoseltamab-phase-12-study-design-in-rr-al-amyloidosis-linkeral22026-02-21T02:00:48.000Zhttps://www.regeneronmedical.com/content/a1bPr000004VxPjIAK/ussrd-linvoseltamab-ingredients-and-formulation2026-02-21T02:00:48.000Zhttps://www.regeneronmedical.com/content/a1bPr000004VxPkIAK/ussrd-linvoseltamab-description-of-the-molecule-and-drug-product2026-02-21T02:00:48.000Zhttps://www.regeneronmedical.com/content/a1bPr000004WOmTIAW/srdevkeezasevere-hypertriglyceridemia2026-02-22T02:00:41.000Zhttps://www.regeneronmedical.com/content/a1bPr000004WOmUIAW/video-of-cutaneous-squamous-cell-carcinoma-cscc-pathophysiology2026-02-21T02:00:47.000Zhttps://www.regeneronmedical.com/content/a1bPr000004WOmVIAW/video-of-basal-cell-carcinoma-epidemiology2026-02-21T02:00:47.000Zhttps://www.regeneronmedical.com/content/a1bPr000004WOmWIAW/video-of-cutaneous-squamous-cell-carcinoma-cscc-epidemiology2026-02-21T02:00:47.000Zhttps://www.regeneronmedical.com/content/a1bPr000004Xe4PIAS/srd-dupilumab-general-efficacy-afrs2026-03-05T02:00:28.000Zhttps://www.regeneronmedical.com/content/a1bPr000004Xe4QIAS/srd-dupilumab-general-infections-afrs2026-02-25T15:09:44.000Zhttps://www.regeneronmedical.com/content/a1bPr000004Xe4RIAS/srd-dupilumab-pharmacokinetics-and-pharmacodynamics-afrs2026-02-25T15:09:44.000Zhttps://www.regeneronmedical.com/content/a1bPr000004Xe4SIAS/srd-dupilumab-general-safety-afrs2026-03-05T02:00:29.000Zhttps://www.regeneronmedical.com/content/a1bPr000004Xe4TIAS/srd-dupilumab-conjunctivitis-ast-np-eoe-copd-afrs2026-02-25T15:09:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000004YAyjIAG/srd-dupilumab-pharmacokinetics-and-pharmacodynamics-ad-ped-ad2026-02-26T02:01:01.000Zhttps://www.regeneronmedical.com/content/a1bPr000004YAykIAG/srd-dupilumab-manufacturing-process2026-02-27T02:00:23.000Zhttps://www.regeneronmedical.com/content/a1bPr000004YAylIAG/srd-dupilumab-general-efficacy-haft-ad2026-02-26T02:01:02.000Zhttps://www.regeneronmedical.com/content/a1bPr000004YAymIAG/srd-dupilumab-general-safety-haft-ad2026-02-26T02:01:02.000Zhttps://www.regeneronmedical.com/content/a1bPr000004YAynIAG/srd-dupilumab-q2w-dosing-eoe2026-02-26T02:01:02.000Zhttps://www.regeneronmedical.com/content/a1bPr000004YAyoIAG/srd-dupilumab-general-infections-eoe-ped-eoe2026-02-27T02:00:23.000Zhttps://www.regeneronmedical.com/content/a1bPr000004YAypIAG/srd-dupilumab-general-efficacy-copd2026-02-26T02:01:02.000Zhttps://www.regeneronmedical.com/content/a1bPr000004YAyqIAG/srd-dupilumab-smoking-status-copd2026-02-27T02:00:23.000Zhttps://www.regeneronmedical.com/content/a1bPr000004YAyrIAG/srd-dupilumab-increased-and-decreased-dose-frequency-ad-ped-ad2026-02-27T02:00:23.000Zhttps://www.regeneronmedical.com/content/a1bPr000004YAysIAG/srd-dupilumab-concomitant-allergen-immunotherapy-environmental2026-02-26T02:01:03.000Zhttps://www.regeneronmedical.com/content/a1bPr000004YAytIAG/srd-dupilumab-conjunctivitis-in-pediatric-atopic-dermatitis-ped-ad2026-02-26T02:01:03.000Zhttps://www.regeneronmedical.com/content/a1bPr000004YAyuIAG/srd-dupilumab-general-safety-pn2026-02-27T02:00:23.000Zhttps://www.regeneronmedical.com/content/a1bPr000004YAyvIAG/srd-dupilumab-ad-exacerbations-ad-ped-ad2026-02-27T02:00:23.000Zhttps://www.regeneronmedical.com/content/a1bPr000004YAywIAG/srd-dupilumab-arthritis-ad-ped-ad2026-02-26T02:01:04.000Zhttps://www.regeneronmedical.com/content/a1bPr000004YAyxIAG/srd-dupilumab-conjunctivitis-in-adult-atopic-dermatitis-ad2026-02-27T02:00:23.000Zhttps://www.regeneronmedical.com/content/a1bPr000004Yh0DIAS/a1bpr000004yh0d2026-02-27T09:14:28.000Zhttps://www.regeneronmedical.com/content/a1bPr000004Yh0EIAS/a1bpr000004yh0e2026-02-27T09:14:28.000Zhttps://www.regeneronmedical.com/content/a1bPr000004Yh0FIAS/a1bpr000004yh0f2026-02-27T09:14:28.000Zhttps://www.regeneronmedical.com/content/a1bPr000004ZcXxIAK/video-overview-of-environmental-and-occupational-risk-factors-in-nsclc2026-03-04T02:00:52.000Zhttps://www.regeneronmedical.com/content/a1bPr000004a6nmIAA/ophthalmology-modular-content-rop-dse-mini-slide-deck2026-03-05T02:00:29.000Zhttps://www.regeneronmedical.com/content/a1bPr000004b7Y5IAI/pro-specialist-hofh-campaign-cascade-screening-video-dec-20242026-03-31T10:42:08.000Zhttps://www.regeneronmedical.com/content/a1bPr000004ceTZIAY/video-overview-of-melanoma-disparities2026-04-10T15:09:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004d9h3IAA/procrs-fact-sheet-risks-factors-and-management2026-04-07T21:14:23.000Zhttps://www.regeneronmedical.com/content/a1bPr000004e20nIAA/melanoma-pathophysiology-infographic2026-04-10T15:12:30.000Zhttps://www.regeneronmedical.com/content/a1bPr000004fCirIAE/promelanoma-epidemiology-infographic2026-03-27T01:00:33.000Zhttps://www.regeneronmedical.com/content/a1bPr000004fctRIAQ/srdveopozingredients-and-formulation2026-03-20T01:00:39.000Zhttps://www.regeneronmedical.com/content/a1bPr000004fctSIAQ/srdveopozshelf-life2026-03-20T01:00:39.000Zhttps://www.regeneronmedical.com/content/a1bPr000004fctTIAQ/srdveopozuse-with-other-biologics-and-drug-interactions2026-03-20T01:00:39.000Zhttps://www.regeneronmedical.com/content/a1bPr000004fctUIAQ/srdveopozdosage-and-administration2026-03-20T01:00:39.000Zhttps://www.regeneronmedical.com/content/a1bPr000004fctVIAQ/srdveopozvaccinations-and-infection-risk2026-03-20T01:00:40.000Zhttps://www.regeneronmedical.com/content/a1bPr000004fetdIAA/a1bpr000004fetd2026-03-19T09:45:22.000Zhttps://www.regeneronmedical.com/content/a1bPr000004fevFIAQ/a1bpr000004fevf2026-03-24T19:37:22.000Zhttps://www.regeneronmedical.com/content/a1bPr000004fevGIAQ/a1bpr000004fevg2026-03-24T19:36:29.000Zhttps://www.regeneronmedical.com/content/a1bPr000004fevHIAQ/a1bpr000004fevh2026-03-24T19:39:00.000Zhttps://www.regeneronmedical.com/content/a1bPr000004fevIIAQ/a1bpr000004fevi2026-03-19T09:47:48.000Zhttps://www.regeneronmedical.com/content/a1bPr000004fevJIAQ/a1bpr000004fevj2026-03-19T09:47:48.000Zhttps://www.regeneronmedical.com/content/a1bPr000004fevKIAQ/a1bpr000004fevk2026-03-19T09:47:48.000Zhttps://www.regeneronmedical.com/content/a1bPr000004fevLIAQ/a1bpr000004fevl2026-04-01T09:25:52.000Zhttps://www.regeneronmedical.com/content/a1bPr000004fevMIAQ/a1bpr000004fevm2026-04-01T09:25:52.000Zhttps://www.regeneronmedical.com/content/a1bPr000004fevNIAQ/a1bpr000004fevn2026-04-01T09:25:52.000Zhttps://www.regeneronmedical.com/content/a1bPr000004g4RVIAY/procervical-cancer-epi-path-mini-deck2026-03-20T01:00:40.000Zhttps://www.regeneronmedical.com/content/a1bPr000004hmtWIAQ/pronsclc-disparities-infographic2026-03-26T01:00:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000004hmtXIAQ/cscc-treatment-modalities-infographic2026-03-26T01:00:35.000Zhttps://www.regeneronmedical.com/content/a1bPr000004iL4sIAE/melanoma-infographic-melanoma-risks-and-outcomes-in-the-us2026-04-07T21:13:26.000Zhttps://www.regeneronmedical.com/content/a1bPr000004jFILIA2/auditory-content-nonsyndromic-hearing-loss-infographic2026-04-10T15:29:24.000Zhttps://www.regeneronmedical.com/content/a1bPr000004k6krIAA/ussrd-linvoseltamab-phase-12-study-design-and-results-in-rrmm-linkermm12026-03-31T01:00:24.000Zhttps://www.regeneronmedical.com/content/a1bPr000004k9CTIAY/regeneron-genetics-center-fact-sheet2026-03-31T10:04:14.000Zhttps://www.regeneronmedical.com/content/a1bPr000004k9CUIAY/regeneron-velocisuitesupsup-flyer2026-03-31T10:04:14.000Zhttps://www.regeneronmedical.com/content/a1bPr000004kr2GIAQ/srd-dupilumab-general-safety-ped-eoe2026-04-02T01:00:21.000Zhttps://www.regeneronmedical.com/content/a1bPr000004ktjxIAA/safety-and-efficacy-of-odronextamab-in-patients-with-relapsed-or-refractory-foll2026-04-01T09:21:41.000Zhttps://www.regeneronmedical.com/content/a1bPr000004ktjyIAA/firstline-cemiplimab-for-locally-advanced-nsclc-updated-subgroup-analyses-from2026-04-01T09:21:41.000Zhttps://www.regeneronmedical.com/content/a1bPr000004ktjzIAA/review-of-patientreported-outcomes-in-empowerlung-1-in-patients-with-advanced2026-04-01T09:21:41.000Zhttps://www.regeneronmedical.com/content/a1bPr000004ktonIAA/rvo-brvo-vs-crvo2026-04-01T09:23:23.000Zhttps://www.regeneronmedical.com/content/a1bPr000004ktooIAA/rvo-epidemiology2026-04-01T09:23:23.000Zhttps://www.regeneronmedical.com/content/a1bPr000004lR5iIAE/prosquamous-vs-basal-cell-carcinomas-in-skin-cancer-infographic2026-04-02T01:00:22.000Zhttps://www.regeneronmedical.com/content/a1bPr000004luvhIAA/srdeylea-hdprimary-results-from-elara-study-at-24-weeks2026-04-03T01:00:40.000Zhttps://www.regeneronmedical.com/content/a1bPr000004luviIAA/srdeylea-hdextended-dosing-intervals-q16w-in-wet-amd-or-dme2026-04-03T01:00:40.000Zhttps://www.regeneronmedical.com/content/a1bPr000004luvjIAA/ussrd-linvoseltamab-outcomes-by-number-of-prior-lines-of-therapy-in-linkermm2026-04-03T01:00:41.000Zhttps://www.regeneronmedical.com/content/a1bPr000004nRj7IAE/procochlea-animationmed-affairs2026-04-08T01:00:46.000Zhttps://www.regeneronmedical.com/content/a1bPr000004p3kjIAA/srdpraluentpotential-risks-of-low-ldlc-25-mgdl-and-15-mgdl2026-04-11T01:00:30.000Zhttps://www.regeneronmedical.com/content/a1bPr000004p3kkIAA/srdpraluentfluflulike-illness2026-04-11T01:00:30.000Zhttps://www.regeneronmedical.com/content/a1bPr000004p3klIAA/proophthalmology-modular-content-rvo-dse-mini-slide-deck2026-04-11T01:00:30.000Zhttps://www.regeneronmedical.com/content/a1bPr000004p3kmIAA/pronsclc-genetic-subtypes-mini-deck2026-04-11T01:00:30.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sX9ZIAU/linvoseltamab-versus-realworld-international-myeloma-working-group-standardof2026-04-17T11:13:58.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sX9aIAE/effectiveness-of-linvoseltamab-versus-realworld-standardofcare-in-tripleclas2026-04-17T11:13:58.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEPIA2/clinical-and-patientreported-outcomes-in-cpost-phase-3-trial-of-adjuvant-cemi2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEQIA2/cemiplimbrwlc-survivorship-and-epidemiology-case-a-prospective-noninterven2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXERIA2/a-multicentre-openlabel-phase-2-study-of-intratumoural-tolllike-receptor-9-a2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXESIA2/comparative-economic-analysis-of-bcell-maturation-antigen-bcmatargeted-bispe2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXETIA2/budget-impact-analysis-of-linvoseltamab-for-the-treatment-of-relapsedrefractory2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEUIA2/rapid-and-sustained-efficacy-of-subcutaneously-administered-cemdisiran-without-c2026-04-17T17:01:01.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEVIA2/time-to-treatment-initiation-and-vision-outcomes-in-treatmentna%C3%AFve-eyes-with-ma2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEWIA2/spectrum-latest-clinical-data-from-the-first-global-realworld-study-of-afliber2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEXIA2/spectrum-latest-clinical-data-from-the-first-global-realworld-study-of-afliber2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEYIA2/spectrum-early-realworld-treatment-patterns-with-aflibercept-8-mg-in-patients2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEZIA2/spectrum-uk-cohort-analysis-early-realworld-outcomes-with-aflibercept-8-mg-in2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEaIAM/realworld-use-of-aflibercept-8-mg-in-eyes-with-neovascular-agerelated-macular2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEbIAM/realworld-use-of-aflibercept-8-mg-in-eyes-with-namd-or-dme-analysis-of-the-med2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEcIAM/realworld-use-of-aflibercept-8-mg-in-eyes-with-diabetic-macular-edema-dme-an2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEdIAM/realworld-use-of-aflibercept-8-mg-in-eyes-with-namd-or-dme-analysis-of-the-k2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEeIAM/pulsar-extension-week-156-outcomes-with-aflibercept-8-mg-in-patients-with-namd2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEfIAM/pulsar-extension-sustained-clinical-outcomes-with-reduced-treatment-burden-afte2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEgIAM/pulsar-extension-safety-analysis-of-aflibercept-8-mg-through-156-weeks-in-patie2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEhIAM/pulsar-extension-156week-retinal-fluid-and-ped-outcomes-in-patients-with-namd2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEiIAM/pigment-epithelial-detachment-outcomes-with-aflibercept-8-mg-versus-aflibercept2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEjIAM/intraocular-pressure-outcomes-with-aflibercept-8-mg-and-2-mg-in-patients-with-di2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEkIAM/impact-of-baseline-bl-central-retinal-thickness-crt-on-visual-and-anatomic-o2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXElIAM/impact-of-baseline-bl-bestcorrected-visual-acuity-on-visual-and-anatomic-outc2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEmIAM/highprecision-measurement-of-retinal-sensitivity-by-means-of-10session-athome2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEnIAM/early-global-analysis-of-intraocular-pressure-changes-in-patients-with-namd-and2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEoIAM/early-clinical-results-in-spain-of-the-global-realworld-spectrum-study-of-aflib2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEpIAM/clinical-outcomes-of-aflibercept-8-mg-for-retinal-vein-occlusion-in-subgroups-de2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEqIAM/budget-impact-analysis-of-patients-with-namd-or-dme-who-may-require-monthly-dosi2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXErIAM/aflibercept-8-mg-in-macular-edema-following-retinal-vein-occlusion-mefrvo-642026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEsIAM/a-novel-systemic-approach-to-geographic-atrophy-with-pozelimab-in-combination-wi2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sXEtIAM/spectrum-early-realworld-treatment-patterns-with-aflibercept-8-mg-in-patients2026-04-17T11:17:57.000Zhttps://www.regeneronmedical.com/content/a1bPr000004sk0LIAQ/safety-and-efficacy-of-dboto-gene-therapy-in-children-with-profound-deafness-du2026-04-17T15:41:40.000Zhttps://www.regeneronmedical.com/content/a1bPr000004t5zFIAQ/proclinical-presentation-diagnosis-of-rvo-mini-slide-deck2026-04-18T01:00:42.000Z